Elisa G. Carvajal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elisa G. Carvajal has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Christopher W. Cairo
Department of Chemistry, University of Alberta, Edmonton, Alberta, Canada
2 shared publications - Alexey V. Pshezhetsky
CHU Sainte-Justine Research Center, Université de Montréal, Montreal, H3T 1C5, QC, Canada
1 shared publication - Antoine Caillon
CHU Sainte-Justine Research Center, Université de Montréal, Montreal, H3T 1C5, QC, Canada
1 shared publication - Aymeric Fabié
CHU Sainte-Justine Research Center, Université de Montréal, Montreal, H3T 1C5, QC, Canada
1 shared publication - Diogo Poroca
CHU Sainte-Justine Research Center, Université de Montréal, Montreal, H3T 1C5, QC, Canada
1 shared publication - Lorena Carvelli
CHU Sainte-Justine Research Center, Université de Montréal, Montreal, H3T 1C5, QC, Canada
1 shared publication
Latest Publications
- Open Access
Inhibition of macrophage neuraminidase 1 protects against immune thrombocytopenia by limiting platelet clearance
Immune thrombocytopenia purpura (ITP) is an autoimmune disorder characterized by a reduction in circulating platelet levels, primarily due to generation of autoantibodies to platelet surface antigens followed by their spleen macrophage-mediated clearance. Emerging evidence implicates neuraminidase (sialidase) enzymes including neuraminidase 1 (NEU1) in platelet clearance and ITP severity; however, the underlying cellular mechanisms remain unknown. Using tissue-specific NEU1 knockout mouse models, we studied the contribution of platelet and macrophage NEU1 to ITP pathogenesis and evaluated whether pharmacological inhibition of NEU1 could preserve platelet counts in a murine ITP model. Constitutive and macrophage-specific, but not platelet-specific, NEU1 knockout mice showed a protection against reduction of platelet counts in the passive ITP model suggesting that macrophage, but not platelet, NEU1 promotes platelet clearance. Genetic deletion or pharmacological blockade of macrophage NEU1 also reduced platelet phagocytosis by cultured macrophages in vitro. The selective NEU1 inhibitor CG33301 protected mice against anti-CD41a antibody-induced thrombocytopenia and showed a higher efficacy compared to pan neuraminidase inhibitor oseltamivir phosphate. Our results demonstrate that the macrophage pool of NEU1 plays a central role in platelet clearance by splenocytes during ITP by activating their phagocytosis and suggest that selective NEU1 inhibition may be a promising therapeutic strategy for this disease.
Open AccessInhibition of macrophage neuraminidase 1 protects against immune thrombocytopenia by limiting platelet clearance
Immune thrombocytopenia purpura (ITP) is an autoimmune disorder characterized by a reduction in circulating platelet levels, primarily due to generation of autoantibodies to platelet surface antigens followed by their spleen macrophage-mediated clearance. Emerging evidence implicates neuraminidase (sialidase) enzymes including neuraminidase 1 (NEU1) in platelet clearance and ITP severity; however, the underlying cellular mechanisms remain unknown. Using tissue-specific NEU1 knockout mouse models, we studied the contribution of platelet and macrophage NEU1 to ITP pathogenesis and evaluated whether pharmacological inhibition of NEU1 could preserve platelet counts in a murine ITP model. Constitutive and macrophage-specific, but not platelet-specific, NEU1 knockout mice showed a protection against reduction of platelet counts in the passive ITP model suggesting that macrophage, but not platelet, NEU1 promotes platelet clearance. Genetic deletion or pharmacological blockade of macrophage NEU1 also reduced platelet phagocytosis by cultured macrophages in vitro. The selective NEU1 inhibitor CG33301 protected mice against anti-CD41a antibody-induced thrombocytopenia and showed a higher efficacy compared to pan neuraminidase inhibitor oseltamivir phosphate. Our results demonstrate that the macrophage pool of NEU1 plays a central role in platelet clearance by splenocytes during ITP by activating their phagocytosis and suggest that selective NEU1 inhibition may be a promising therapeutic strategy for this disease.
- Open Access
- 7 May 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (13) , e202500099
Improved C5‐Amide Bioisosteres for Human Neuraminidase 1 Inhibitors Based on 2‐Deoxy‐2,3‐Didehydro‐N‐Acetyl Neuraminic Acid
Neuraminidase enzymes (NEU) play a crucial role in many physiological and pathological conditions. Humans have four isoenzymes of NEU, and their specific roles continue to be investigated. Isoenzyme‐selective inhibitors are needed as research tools and may lead to future therapeutics. A series of new candidate inhibitors are tested by replacing the C5‐amide of 2‐deoxy‐2,3‐dididehydro‐N‐acetyl neuraminic acid with amide bioisosteres. Design of candidate inhibitors is accomplished using substituents that are components of previously identified NEU inhibitors combined with alternative amide bioisosteres. Compounds are tested for inhibition of the four human NEU, and inhibitory activities are compared to reference amide compounds. 1,4‐Disubstituted‐1,2,3‐triazole is the best bioisostere observed for inhibitors of NEU1. Inhibitor 542 shows high potency for NEU1 (Ki = 0.4 ± 0.1 μM) and give significant improvement in selectivity compared to the reference amide compound 502. Additionally, compound 542 has improved lipophilic characteristics, which could provide improved pharmacokinetic properties. Screening of these inhibitors also identify a selective NEU2 inhibitor 543 (Ki = 2.6 ± 0.6 μM), illustrating that amide bioisostere replacement can identify improved inhibitors for multiple NEU isoenzymes.
- 7 May 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (13) , e202500099
Open AccessImproved C5‐Amide Bioisosteres for Human Neuraminidase 1 Inhibitors Based on 2‐Deoxy‐2,3‐Didehydro‐N‐Acetyl Neuraminic Acid
Neuraminidase enzymes (NEU) play a crucial role in many physiological and pathological conditions. Humans have four isoenzymes of NEU, and their specific roles continue to be investigated. Isoenzyme‐selective inhibitors are needed as research tools and may lead to future therapeutics. A series of new candidate inhibitors are tested by replacing the C5‐amide of 2‐deoxy‐2,3‐dididehydro‐N‐acetyl neuraminic acid with amide bioisosteres. Design of candidate inhibitors is accomplished using substituents that are components of previously identified NEU inhibitors combined with alternative amide bioisosteres. Compounds are tested for inhibition of the four human NEU, and inhibitory activities are compared to reference amide compounds. 1,4‐Disubstituted‐1,2,3‐triazole is the best bioisostere observed for inhibitors of NEU1. Inhibitor 542 shows high potency for NEU1 (Ki = 0.4 ± 0.1 μM) and give significant improvement in selectivity compared to the reference amide compound 502. Additionally, compound 542 has improved lipophilic characteristics, which could provide improved pharmacokinetic properties. Screening of these inhibitors also identify a selective NEU2 inhibitor 543 (Ki = 2.6 ± 0.6 μM), illustrating that amide bioisostere replacement can identify improved inhibitors for multiple NEU isoenzymes.